About N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1
N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1 (B4GALNT4) is a protein
from Homo sapiens identified by UniProt accession
Q76KP1, 1039 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1 |
|---|
| UniProt accession | Q76KP1 |
|---|
| Gene | B4GALNT4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1039 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (25)
Diseases linked to this target (Open Targets).
- unipolar depression · score 0.20
- alkaline phosphatase measurement · score 0.19
- lean body mass · score 0.14
- triglyceride measurement · score 0.12
- creatinine measurement · score 0.08
- high density lipoprotein cholesterol measurement · score 0.08
- HbA1c measurement · score 0.05
- non-small cell lung carcinoma · score 0.04
- esophageal squamous cell carcinoma · score 0.04
- apolipoprotein A 1 measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q76KP1-F1 | alphafold | PREDICTED | 69.84 | — |
Amino-acid sequence (1039 residues)
MPRLPVKKIR KQMKLLLLLL LLSCAAWLTY VHLGLVRQGR ALRQRLGYGR DGEKLTSETD GRGVHAAPST QRAEDSSESR EEEQAPEGRD LDMLFPGGAG RLPLNFTHQT PPWREEYKGQ VNLHVFEDWC GGAVGHLRRN LHFPLFPHTR TTVKKLAVSP KWKNYGLRIF GFIHPARDGD VQFSVASDDN SEFWLSLDES PAAAQLVAFV GKTGSEWTAP GEFTKFSSQV SKPRRLMASR RYYFELLHKQ DDRGSDHVEV GWRAFLPGLK FEVISSAHIS LYTDESALKM DHVAHVPQSP ASHVGGRPPQ EETSADMLRP DPRDTFFLTP RMESSSLENV LEPCAYAPTY VVKDFPIARY QGLQFVYLSF VYPNDYTRLT HMETDNKCFY RESPLYLERF GFYKYMKMDK EEGDEDEEDE VQRRAFLFLN PDDFLDDEDE GELLDSLEPT EAAPPRSGPQ SPAPAAPAQP GATLAPPTPP RPRDGGTPRH SRALSWAARA ARPLPLFLGR APPPRPAVEQ PPPKVYVTRV RPGQRASPRA PAPRAPWPPF PGVFLHPRPL PRVQLRAPPR PPRPHGRRTG GPQATQPRPP ARAQATQGGR EGQARTLGPA APTVDSNLSS EARPVTSFLS LSQVSGPQLP GEGEEEEEGE DDGAPGDEAA SEDSEEAAGP ALGRWREDAI DWQRTFSVGA VDFELLRSDW NDLRCNVSGN LQLPEAEAVD VTAQYMERLN ARHGGRFALL RIVNVEKRRD SARGSRFLLE LELQERGGGR LRLSEYVFLR LPGARVGDAD GESPEPAPAA SVRPDGRPEL CRPLRLAWRQ DVMVHFIVPV KNQARWVAQF LADMAALHAR TGDSRFSVVL VDFESEDMDV ERALRAARLP RYQYLRRTGN FERSAGLQAG VDAVEDASSI VFLCDLHIHF PPNILDGIRK HCVEGRLAFA PVVMRLSCGS SPRDPHGYWE VNGFGLFGIY KSDFDRVGGM NTEEFRDQWG GEDWELLDRV LQAGLEVERL RLRNFYHHYH SKRGMWSVRS RKGSRTGAS
Explore N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets